Liquidia’s stock rebounded after the company reached a settlement with United Therapeutics that ended six lawsuits tied to Yutrepia (treprostinil) patent and antitrust claims. As part of the deal, Liquidia agreed to pay $380.7 million to settle antitrust litigation and to remove pulmonary hypertension associated with interstitial lung disease (PH-ILD) from the product’s label, while keeping Yutrepia for pulmonary arterial hypertension.